摘要
肺癌是世界上发病率和死亡率最高的肿瘤,我国是肺癌的高发国家。铂是目前最常用的非小细胞肺癌(NSCLC)肿瘤化疗药物。铂类药物的耐药是多种机制共同作用的结果。人乳腺癌易感基因1(BRCA1)是一种抑癌基因,有细胞损伤修复、细胞蛋白调控、细胞凋亡等多重作用。BRCA1是非小细胞肺癌患者铂类药物敏感性的最佳敏感指标之一。BRCA1与肿瘤分期联合检测可作为预测患者生存期。
Lung cancer is the morbidity and mortality in the world's highest tumor,China is a country of high incidence of lung cancer.Platinum is the most commonly drug used in non-small cell lung cancer(non-small-cell lung cancer,NSCLC) chemotherapy.Platinum drug resistance is the result of a variety of mechanisms together.Cancer susceptibility,breast cancer susceptibility gene1(BIRADS gene1,BRCA1) is a tumor suppressor gene,and has multiple roles,such as cell damage repair,cell protein regulation,apoptosis.BRCA1 is one of platinum sensitive indicators of drug sensitivity for non-small cell lung cancer patients.The joint detection of BRCA1 and tumor stage may be as a predictor of patient survival.
出处
《四川解剖学杂志》
2012年第2期51-54,共4页
Sichuan Journal of Anatomy
关键词
非小细胞肺癌
人乳腺癌易感基因1
铂
耐药
Non-small-cell lung cancer(NSCLC)
Breast cancer susceptibility gene1(BRCA1)
Platinum
Drug resistance